BiotechTube
Nanobiosym

Nanobiosym

Cambridge, United States· Est.
nanobiosym.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $8.5M

Overview

Nanobiosym is a long-standing private biotechnology firm leveraging nanobiophysics to develop transformative diagnostic technologies. Its flagship platform, Gene-RADAR®, is designed to provide rapid, accurate, and portable molecular diagnostic testing, positioning the company in the decentralized and point-of-care testing market. Led by founder and CEO Dr. Anita Goel, the company has gained recognition through awards and partnerships, though it operates in a highly competitive and capital-intensive diagnostics landscape with a technology platform that has yet to achieve widespread commercial deployment.

Infectious Diseases

Technology Platform

Gene-RADAR®: A nanotechnology-based platform for rapid, accurate, and portable molecular diagnostic testing at the point-of-care.

Funding History

3
Total raised:$8.5M
Seed$5M
Grant$1.5M
Grant$2M

Opportunities

The global shift towards decentralized and point-of-care diagnostics, accelerated by the COVID-19 pandemic, presents a massive market opportunity.
The Gene-RADAR® platform's potential for rapid, portable testing could address critical needs in both developed and resource-limited healthcare settings, enabling personalized health monitoring and pandemic response.

Risk Factors

Key risks include failure to transition the Gene-RADAR® technology from prototype to a commercially viable, regulated product, intense competition from established diagnostics firms and well-funded startups, and potential challenges in scaling manufacturing and global distribution as a smaller private company.

Competitive Landscape

Nanobiosym competes in the crowded point-of-care molecular diagnostics market against large, established players like Abbott (ID NOW), Cepheid (GeneXpert), and Roche, as well as numerous startups. Differentiation hinges on the performance, cost, portability, and breadth of tests enabled by its proprietary Gene-RADAR® nanotechnology platform.

More companies in Diagnostics & Precision Medicine →More companies in United States →